{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:12:13Z","timestamp":1790892733948,"version":"4.1.0"},"reference-count":163,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clinthera.2023.05.010","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T13:58:49Z","timestamp":1689429529000},"page":"826-840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Pharmacologic Treatment Strategies in Psoriatic Arthritis"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1889-9619","authenticated-orcid":false,"given":"G.","family":"Ayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Macit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Proft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clinthera.2023.05.010_bib0001","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2012-201706","article-title":"High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires","volume":"72","author":"Haroon","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0004","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.clinthera.2023.05.010_bib0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"25","key":"10.1016\/j.clinthera.2023.05.010_bib0006","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat New Biol"},{"issue":"3","key":"10.1016\/j.clinthera.2023.05.010_bib0007","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","article-title":"Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases","volume":"16","author":"Hardy","year":"2020","journal-title":"Nature Reviews Rheumatology"},{"issue":"3","key":"10.1016\/j.clinthera.2023.05.010_bib0008","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.clinthera.2023.05.010_bib0009","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI992","article-title":"Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B","volume":"101","author":"Wahl","year":"1998","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.clinthera.2023.05.010_bib0010","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/1529-0131(200009)43:9<1941::AID-ANR4>3.0.CO;2-O","article-title":"The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis","volume":"43","author":"Rodenburg","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.clinthera.2023.05.010_bib0011","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1172\/JCI1554","article-title":"Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5\u2032-nucleotidase-mediated conversion of adenine nucleotides","volume":"101","author":"Morabito","year":"1998","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.clinthera.2023.05.010_bib0012","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: mode of action in the treatment of rheumatoid arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"6 Suppl 3","key":"10.1016\/j.clinthera.2023.05.010_bib0013","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0049-0172(92)90009-3","article-title":"Mechanisms of action of cyclosporine and effects on connective tissues","volume":"21","author":"Russell","year":"1992","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.jidsymp.5650029","article-title":"Tumor necrosis factor blockade: mechanism of action","volume":"12","author":"Gottlieb","year":"2007","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5114\/ada.2016.61599","article-title":"Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases","volume":"33","author":"Wasilewska","year":"2016","journal-title":"Postepy Dermatol Alergol"},{"issue":"2","key":"10.1016\/j.clinthera.2023.05.010_bib0016","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0017","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0018","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar2416","article-title":"Abatacept in the treatment of rheumatoid arthritis","volume":"10","author":"Buch","year":"2008","journal-title":"Arthritis Research & Therapy"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.05.010_bib0019","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic Mechanisms of JAK Inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr J Rheumatol"},{"issue":"12","key":"10.1016\/j.clinthera.2023.05.010_bib0020","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0021","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/BOR.0b013e32832c7832","article-title":"Psoriatic arthritis assessment and treatment update","volume":"21","author":"Mease","year":"2009","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"10.1016\/j.clinthera.2023.05.010_bib0022","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/acr.20162","article-title":"Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0023","first-page":"1126","article-title":"The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada","volume":"31","author":"Gladman","year":"2004","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0024","first-page":"62","article-title":"Reliability of measurements of active and damaged joints in psoriatic arthritis","volume":"17","author":"Gladman","year":"1990","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0025","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.bor.0000129716.12154.06","article-title":"Assessment of outcome in psoriatic arthritis","volume":"16","author":"Taylor","year":"2004","journal-title":"Current Opinion in Rheumatology"},{"issue":"5","key":"10.1016\/j.clinthera.2023.05.010_bib0026","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.160387","article-title":"Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab","volume":"44","author":"Mease","year":"2017","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0027","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.semarthrit.2021.06.008","article-title":"Outcome measures used in psoriatic arthritis registries and cohorts: A systematic literature review of 27 registries or 16,183 patients","volume":"51","author":"Aouad","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0028","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0029","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.bor.0000167753.01168.bd","article-title":"Classification of the spondyloarthropathies","volume":"17","author":"Healy","year":"2005","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"10.1016\/j.clinthera.2023.05.010_bib0030","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 11","key":"10.1016\/j.clinthera.2023.05.010_bib0031","first-page":"S64","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0032","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.clinthera.2023.05.010_bib0033","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.clinthera.2023.05.010_bib0034","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrrheum.2012.56","article-title":"Spondyloarthritis: Is methotrexate effective in psoriatic arthritis?","volume":"8","author":"Mease","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.clinthera.2023.05.010_bib0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3899\/jrheum.150614","article-title":"Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study","volume":"43","author":"Coates","year":"2016","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.clinthera.2023.05.010_bib0036","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0037","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2665-9913(22)00329-0","article-title":"Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial","volume":"5","author":"Koehm","year":"2023","journal-title":"The Lancet Rheumatology"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0038","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/rheumatology\/ken059","article-title":"Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs","volume":"47","author":"Cantini","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0039","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/ard.2009.113308","article-title":"Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis","volume":"69","author":"Lie","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.clinthera.2023.05.010_bib0040","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0041","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.clinthera.2023.05.010_bib0042","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","article-title":"Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)","volume":"77","author":"Nash","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0043","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.clinthera.2023.05.010_bib0044","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"10.1016\/j.clinthera.2023.05.010_bib0045","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clinthera.2023.05.010_bib0046","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clinthera.2023.05.010_bib0047","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.clinthera.2023.05.010_bib0048","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/annrheumdis-2018-214746","article-title":"Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate","volume":"78","author":"van Mens","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0049","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2019-216500","article-title":"GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis","volume":"79","author":"Vieira-Sousa","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.clinthera.2023.05.010_bib0050","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"9227","key":"10.1016\/j.clinthera.2023.05.010_bib0051","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clinthera.2023.05.010_bib0052","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0053","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.clinthera.2023.05.010_bib0054","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0055","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"9999","key":"10.1016\/j.clinthera.2023.05.010_bib0056","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0057","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10230","key":"10.1016\/j.clinthera.2023.05.010_bib0058","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"10230","key":"10.1016\/j.clinthera.2023.05.010_bib0059","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clinthera.2023.05.010_bib0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.clinthera.2023.05.010_bib0061","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.clinthera.2023.05.010_bib0062","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"9894","key":"10.1016\/j.clinthera.2023.05.010_bib0063","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0064","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0065","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.clinthera.2023.05.010_bib0066","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10235","key":"10.1016\/j.clinthera.2023.05.010_bib0067","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0068","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0069","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.clinthera.2023.05.010_bib0070","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/acr.23174","article-title":"Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0071","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/keaa663","article-title":"PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis","volume":"60","author":"Ayan","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0072","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13075-017-1399-5","article-title":"The association between sonographic enthesitis and radiographic damage in psoriatic arthritis","volume":"19","author":"Polachek","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0073","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000669","article-title":"Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies","volume":"4","author":"Gladman","year":"2018","journal-title":"RMD Open"},{"issue":"16","key":"10.1016\/j.clinthera.2023.05.010_bib0074","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clinthera.2023.05.010_bib0075","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"14","key":"10.1016\/j.clinthera.2023.05.010_bib0076","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0077","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.clinthera.2023.05.010_bib0078","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0079","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"10.1016\/j.clinthera.2023.05.010_bib0080","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clinthera.2023.05.010_bib0081","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1093\/rheumatology\/keab285","article-title":"Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies","volume":"60","author":"McGonagle","year":"2021","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.clinthera.2023.05.010_bib0082","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.130163","article-title":"Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era","volume":"40","author":"Gladman","year":"2013","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.clinthera.2023.05.010_bib0083","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","article-title":"Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.clinthera.2023.05.010_bib0084","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard.2003.018184","article-title":"Dactylitis in psoriatic arthritis: a marker for disease severity?","volume":"64","author":"Brockbank","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0085","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2021-220964","article-title":"Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis","volume":"81","author":"Dubash","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0086","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/acr.23905","article-title":"Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis","volume":"72","author":"Husni","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0087","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s41927-022-00298-4","article-title":"Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies","volume":"6","author":"Orbai","year":"2022","journal-title":"BMC Rheumatol"},{"issue":"13","key":"10.1016\/j.clinthera.2023.05.010_bib0088","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"suppl 10","key":"10.1016\/j.clinthera.2023.05.010_bib0089","article-title":"Efficacy of Secukinumab Treatment in Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies [abstract]","volume":"72","author":"Ritchlin","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","article-title":"Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis","volume":"21","author":"Gladman","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.05.010_bib0091","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1136\/annrheumdis-2020-eular.836","article-title":"AB0801\u2005EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES","volume":"79","author":"Mcgonagle","year":"2020","journal-title":"Annals of the Rheumatic Diseases."},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0092","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/rheumatology\/kez457","article-title":"Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?","volume":"59","author":"Feld","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.clinthera.2023.05.010_bib0093","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"suppl 10","key":"10.1016\/j.clinthera.2023.05.010_bib0094","article-title":"Efficacy and Safety of Upadacitinib inPatients with Psoriatic Arthritis and Axial Involvement","volume":"72","author":"Deodhar","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.clinthera.2023.05.010_bib0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-048647","article-title":"Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial","volume":"11","author":"Proft","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2023.05.010_bib0096","first-page":"1838","article-title":"Efficacy of ixekizumab in active psoriatic arthritis (PsA) patients with axial pain starting before age 45: a subgroup analysis of SPIRIT-P1 and SPIRIT-P2 phase 3 clinical trials","volume":"78","author":"Deodhar","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0097","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001149","article-title":"Effects of ustekinumab on spondylitis-associated endpoints in TNFi-na\u00efve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials","volume":"6","author":"Helliwell","year":"2020","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.clinthera.2023.05.010_bib0098","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"The Lancet Rheumatology"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0099","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","article-title":"Efficacy and safety of guselkumab in biologic-na\u00efve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial","volume":"23","author":"Gladman","year":"2022","journal-title":"Trials"},{"issue":"suppl 10","key":"10.1016\/j.clinthera.2023.05.010_sbref0100","article-title":"Use of the BASDAI in Psoriatic Arthritis Patients with and Without Axial Disease","volume":"72","author":"Reddy","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0101","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"9993","key":"10.1016\/j.clinthera.2023.05.010_bib0102","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clinthera.2023.05.010_bib0103","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clinthera.2023.05.010_bib0104","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10198","key":"10.1016\/j.clinthera.2023.05.010_bib0105","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"10201","key":"10.1016\/j.clinthera.2023.05.010_bib0106","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0107","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0108","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0109","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"issue":"10148","key":"10.1016\/j.clinthera.2023.05.010_bib0110","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clinthera.2023.05.010_bib0111","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0112","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ced.14314","article-title":"Management of nail psoriasis","volume":"46","author":"Thomas","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clinthera.2023.05.010_bib0114","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.2147\/DDDT.S136986","article-title":"New insight into the pathogenesis of nail psoriasis and overview of treatment strategies","volume":"11","author":"Ventura","year":"2017","journal-title":"Drug Des Devel Ther."},{"issue":"5","key":"10.1016\/j.clinthera.2023.05.010_bib0115","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1111\/jdv.17931","article-title":"Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1","volume":"36","author":"Kristensen","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0116","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s13555-022-00704-2","article-title":"Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis","volume":"12","author":"Elewski","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.clinthera.2023.05.010_bib0117","first-page":"301","article-title":"Efficacy of anti-tumour necrosis factor-\u03b1 monoclonal antibodies in patients with non-infectious anterior uveitis","volume":"37","author":"Fabiani","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.clinthera.2023.05.010_bib0118","first-page":"438","article-title":"Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations","volume":"50","author":"Jadon","year":"2023","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0119","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.clinthera.2023.05.010_bib0120","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor necrosis factor inhibitors for inflammatory bowel disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clinthera.2023.05.010_bib0121","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clinthera.2023.05.010_bib0122","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"10341","key":"10.1016\/j.clinthera.2023.05.010_bib0123","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0124","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4 Suppl 1","key":"10.1016\/j.clinthera.2023.05.010_bib0125","first-page":"12","article-title":"The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12","volume":"18","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"20","key":"10.1016\/j.clinthera.2023.05.010_bib0126","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clinthera.2023.05.010_bib0127","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"10340","key":"10.1016\/j.clinthera.2023.05.010_bib0128","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"issue":"10340","key":"10.1016\/j.clinthera.2023.05.010_bib0129","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0130","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.clinthera.2023.05.010_bib0131","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.clinthera.2023.05.010_bib0132","first-page":"426","article-title":"Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations","volume":"50","author":"Campanholo","year":"2023","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.clinthera.2023.05.010_bib0133","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1046\/j.1440-1746.2001.02644.x","article-title":"Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury","volume":"16","author":"Langman","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.clinthera.2023.05.010_bib0134","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.140021","article-title":"High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease","volume":"41","author":"Haroon","year":"2014","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.clinthera.2023.05.010_bib0136","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3945\/ajcn.2008.26427","article-title":"Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial","volume":"88","author":"Gisondi","year":"2008","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.clinthera.2023.05.010_bib0137","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3899\/jrheum.130797","article-title":"Depression and anxiety in psoriatic disease: prevalence and associated factors","volume":"41","author":"McDonough","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.05.010_bib0138","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/762921","article-title":"High frequency of fibromyalgia in patients with psoriatic arthritis: a pilot study","volume":"2013","author":"Magrey","year":"2013","journal-title":"Arthritis"},{"issue":"1","key":"10.1016\/j.clinthera.2023.05.010_bib0139","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13075-021-02680-y","article-title":"Sex-specific differences and how to handle them in early psoriatic arthritis","volume":"24","author":"Passia","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.clinthera.2023.05.010_bib0140","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3899\/jrheum.220154","article-title":"Women With Psoriatic Arthritis Experience Higher Disease Burden Than Men: Findings From a Real-World Survey in the United States and Europe","volume":"50","author":"Gossec","year":"2023","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0141","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.clinthera.2023.05.010_bib0142","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keac353","article-title":"Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE","volume":"62","author":"Mease","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"10370","key":"10.1016\/j.clinthera.2023.05.010_bib0143","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"issue":"10370","key":"10.1016\/j.clinthera.2023.05.010_bib0144","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clinthera.2023.05.010_bib0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.clinthera.2023.05.010_bib0146","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/jdv.16932","article-title":"A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)","volume":"35","author":"Pinter","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clinthera.2023.05.010_bib0147","series-title":"OP0258 izokibep (ABY-035) in patients with active psoriatic arthritis\u201316-WEEK results from a phase 2 study","author":"Behrens","year":"2022"},{"issue":"9","key":"10.1016\/j.clinthera.2023.05.010_bib0148","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.05.010_bib0149","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04314544 (accessed March 4, 2023). EaSoTCtPiSWAPAIIBMUNLoMnd."},{"key":"10.1016\/j.clinthera.2023.05.010_bib0150","unstructured":"n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04314531 (accessed March 4, 2023). Easotctpia-TnswapaIIBMUNLoM."},{"issue":"10162","key":"10.1016\/j.clinthera.2023.05.010_bib0151","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clinthera.2023.05.010_bib0152","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1007\/s12325-022-02168-4","article-title":"MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases","volume":"39","author":"Hellstrom","year":"2022","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0153","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"suppl 9","key":"10.1016\/j.clinthera.2023.05.010_bib0154","article-title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components","volume":"74","author":"Kavanaugh","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.clinthera.2023.05.010_bib0155","article-title":"Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial","volume":"74","author":"Mease","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.clinthera.2023.05.010_bib0156","article-title":"Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2\/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial","volume":"73","author":"Mease","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.clinthera.2023.05.010_bib0157","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jbspin.2019.12.004","article-title":"Cardiovascular risk in psoriatic arthritis, a narrative review","volume":"87","author":"Verhoeven","year":"2020","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.clinthera.2023.05.010_bib0158","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.amjms.2017.03.014","article-title":"Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease","volume":"354","author":"Shetty","year":"2017","journal-title":"Am J Med Sci"},{"issue":"6","key":"10.1016\/j.clinthera.2023.05.010_bib0159","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1540-9740.2005.04502.x","article-title":"TNF-alpha inhibitors and congestive heart failure","volume":"4","author":"Behnam","year":"2005","journal-title":"Skinmed"},{"issue":"8","key":"10.1016\/j.clinthera.2023.05.010_bib0160","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.clinthera.2023.05.010_bib0161","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clinthera.2023.05.010_bib0162","first-page":"1432","article-title":"Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination","volume":"40","author":"Galloway","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clinthera.2023.05.010_bib0163","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101809","article-title":"Horizon scan: State-of-the-art therapeutics for psoriatic arthritis","author":"Hutton","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823001984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823001984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:58:46Z","timestamp":1758963526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823001984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":163,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0149291823001984"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.05.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Treatment Strategies in Psoriatic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}